Trial Profile
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 31 Aug 2017
Price :
$35
*
At a glance
- Drugs Ulocuplumab (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- 25 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Feb 2016 New trial record